SFEBES2023 Poster Presentations Neuroendocrinology and Pituitary (74 abstracts)
Characterisation of the Impact of Joint Pain on Patients with Acromegaly
Sophie Hebden 1 , Nawaz Safdar 1 , Megan Heague 1 , Julie Lynch 2 , David Mclaren 2 , Alberto Tresoldi 3 , Kirstie Lithgow 3 , Sandrine Urwyler 3 , Shahzad Akbar 4 , Katie McLoughlin 5 , Tara Kearney 5 , William M Drake 6 , Thozhukat Sathyapalan 4 , Steve Orme 2 , Claire E Higham 7 , Niki Karavitaki 3 , Nikolaos Kyriakakis 2 & Robert Murray 2
1School of Medicine, University of Leeds, Leeds, United Kingdom. 2Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, St James’ University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 3Department of Endocrinology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom. 4Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, United Kingdom. 5Department of Endocrinology, Salford Royal Foundation Trust, Manchester, United Kingdom. 6Centre for Endocrinology, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom. 7Department of Endocrinology, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
Acromegaly is caused by excessive growth hormone (GH) and insulin-like growth factor (IGF-1) secretion. Arthropathy is a leading cause of morbidity and impaired quality of life in acromegalic patients, often persisting despite therapeutic interventions and biochemical control. This cross-sectional study aimed to characterise the extent and impact of arthropathy in terms of pain and functional impairment. Validated questionnaires, including DASH (Disabilities of the Arm, Shoulder and Hand), Oswestry Disability Index, KOOS (Knee Injury and Osteoarthritis Outcome Score) and FFI (Foot Function Index) were completed by 85 patients (45 women; median age 58) with biochemically controlled and uncontrolled acromegaly. Seven patients were excluded due to missing data. An Annotated Human Figure Diagram and Numerical Rating Scale were used to identify painful anatomical sites and assess the severity of joint pain, respectively. Patients with biochemically uncontrolled disease (defined as GH >1 mg/l or raised IGF-1 levels) were compared to patients with biochemically controlled disease. In the preceding 3 months, 90.1% of acromegalic patients reported joint, neck or back pain lasting > 6 weeks. The knee was most commonly affected (63.4%), followed by the lower back (53.5%) and hands/fingers (46.5%). Symmetrical arthropathy was observed in the majority of affected joints, with the exception of the groin and wrist. The median number of painful joints reported was five. The knee was most frequently reported as the most painful joint (29.8%), followed by the lower back (19.3%). Patients with uncontrolled acromegaly showed no statistically significant difference in pain scores compared to patients with biochemically controlled acromegaly across all domains. Clinical arthropathy is widely prevalent among patients with acromegaly, with the knee, lower back and hand/fingers most commonly affected. In our study, biochemical control of acromegaly did not significantly impact on the severity of arthropathy in terms of pain and functional limitation.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more